The FDA has approved rusfertide (Mimrylo) for adult patients with polycythemia vera (PV). 1 ...
August 2026 FDA oncology updates: iberdomide, zanidatamab and daraxonrasib win approvals as fast-track designations ...
The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for adults with essential thrombocythemia (ET), marking the first ...
ASCO's updated guideline on breast cancer follow-up recommends risk-based surveillance intensity and selective mammography ...
Surbhi Sidana, MD, discusses the versatility of iberdomide and the approved Iber-Dd regimen in relapsed multiple myeloma. Surbhi Sidana, MD, associate professor of medicine at Stanford University and ...
FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate ...
Survey of 200+ oncology physicians reveals top burnout drivers—EMR burden, leadership gaps, poor work-life boundaries, and ...
A prospective Canadian study suggests that moving beyond narrow, cancer-specific molecular panels toward broader genomic ...
In an interview with Targeted Oncology™, Marcus Neubauer, MD, of The US Oncology Network, discusses the signs of physician ...
Varsetatug masetecan is a first-in-class ADC that pairs a monoclonal antibody against EpCAM with a topoisomerase 1 inhibitor ...
The recent FDA approval of iberdomide (Zenbexus) represents more than the approval of a single new drug for ...
During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results